Since its establishment, Minkang has always focused on building a comprehensive service system for chronic diseases,and put the leadership of technological innovation first, meanwhile, constantly improving its independent research and development ability. At present, it has completed a number of research and development projects of blood glucose monitoring related products with independent intellectual property rights, and has obtained many national invention patents. This time, Minkang has successfully passed the strict procedures and high-standard review, and won the recognition of “National High-tech Enterprise”, which is not only a high affirmation of the comprehensive ability of Minkang's independent research and development, technological innovation, but also will greatly promote the process of independent innovation and independent research and development of the company.

After more than ten years of development, Minkang has formed four leading domestic technical systems of electrochemistry, photochemistry, colloidal gold and immunofluorescence, and has obtained more than 50 patents and software copyrights. The whole series of products cover the detection of multiple indicators such as blood glucose, blood lipids, blood ketone, uric acid, glycosylated hemoglobin, and rapidly upgrade according to the development path of blood glucose detection - multiple indicators detection - intelligent detection, to create an ecological closed-loop of chronic disease management from monitoring to data analysis to the implementation of diagnosis and treatment programs.

In the future, the company will focus on increasing R&D investment and training talent team to build a new technological innovation system, and provide strong technical support for improving the core competitiveness of the enterprise, enriching its innovation and development potential, and realizing its sustainable development. Minkang will strive to realize the great vision of “building a comprehensive service for chronic diseases”, and continue to improve and forge ahead towards the new goal of “global chronic disease management industry, China’s exemplary benchmarking enterprise”, so as to achieve a new leap.